All In Biotech

Drug Trial Radar · NCT01651871

Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis

A Phase 2, Multicenter, Parallel-Group, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Combination Study Of S-555739 And Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Apr 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 779 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

779

Actual

Start

Jul 2012

Primary completion

Nov 2012

Study completion May 2013

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Jul 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to examine the efficacy and safety of S-555739/cetirizine HCl compared with the individual components and placebo.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • S-555739 Dose 1Drug

  • S-555739 Dose 2Drug

  • Cetirizine HCl Dose 1Drug

  • S-555739 placeboDrug

  • Cetirizine HCl placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in average morning/evening (AM/PM) reflective Total Nasal Symptom Score (rTNSS)Time frame: Change from baseline through the 2-week treatment period (Day 2 through Day 15)
  2. Incidence of adverse events (AEs)Time frame: From Screening period to Week 6 (Follow-up)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.